Elute Authorized for Clinical Trial of Antibiotic Eluting Bone Void Filler

Elute, Inc., announced today it has received authorization from the US Food and Drug Administration (FDA) to use its EP Granules with Tobramycin™ in a pivotal clinical trial.

EP Granules with Tobramycin is a synthetic calcium-salt resorbable bone void filler that is designed to provide 8-week delivery of an antibiotic in a local targeted...

document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.


Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.

Contact Us